However, triple negative breast cancers—the collective term for breast cancers that do not express the estrogen receptor (ER) and the progesterone receptor (PR), and do not overexpress the human epidermal growth factor receptor type 2 (HER 2)—are resistant to most types of targeted therapies. This evidence concerns the gene PGR and breast cancer.